How it works:
Daclatasvir inhibits the NS5A protein of the hepatitis C virus, disrupting viral replication and preventing spread. It is used in combination with other DAAs like sofosbuvir and provides high sustained virologic response (SVR) rates across various genotypes.
Recommended for:
Adults with chronic hepatitis C (all genotypes, especially 1 and 3)
Patients naïve to treatment or with previous treatment failure
Individuals with compensated liver cirrhosis
Those following an interferon-free treatment plan
Chronic hepatitis C in adults, as part of a combination antiviral therapy
Usually combined with sofosbuvir, ribavirin or other DAAs depending on genotype
The drug is taken orally once daily at the same time each day, with or without food. It must be used in combination with other antiviral agents. The duration of treatment is typically 12 to 24 weeks, depending on the HCV genotype and liver condition.
Hypersensitivity to daclatasvir or excipients
Severe hepatic impairment
Pregnancy and breastfeeding
Concurrent use of strong CYP3A4 inducers (e.g., rifampin, carbamazepine)
Patients under 18 years of age
Fatigue, headache
Nausea, diarrhoea
Elevated bilirubin levels
Insomnia
Rash, pruritus
Anaemia (in combination with ribavirin)
Increased liver enzymes (ALT, AST)
